Table 2 Snapshot analysis of participants after ART treatment
Characteristic | 2DR | 3DR | P value |
|---|---|---|---|
HIV-1 RNA (< 50 copies/mL) | |||
Week 12 | 25 (92.5%) | 15 (53.57%) | 0.003 |
Week 24 | 26 (100%) | 20 (83.3%) | 0.046 |
Week48 | 24 (100%) | 24 (100%) | 1.000 |
Change From Baseline in CD4 + count (cells/μL) | |||
Week 12 | 125.46 ± 149.38 | 41.2 ± 110.60 | 0.026 |
Week 24 | 209.68 ± 175.88 | 73.28 ± 162.40 | 0.020 |
Week48 | 204.73 ± 287.32 | 163.21 ± 121.15 | 0.805 |
Change From Baseline in CD4/CD8 ratio | |||
Week 12 | 0.11 (0.02–0.31) | 0.21 (0.11–0.35) | 0.058 |
Week 24 | 0.15 (0.09–0.36) | 0.26 (0.12–0.49) | 0.170 |
Week48 | 0.13 (0.07–0.39) | 0.23 (0.10–0.61) | 0.492 |
Change From Baseline to week 48 in Laboratory Results | |||
ALT | − 3.2 (− 4.55–1.1) | 5 (− 0.85–16.35) | 0.004 |
AST | − 4.38 ± 7.64 | 1.11 ± 10.41 | 0.217 |
Cystatin | − 0.1 ± 0.122 | − 0.07 ± 0.10 | 0.439 |
Urea | − 0.01 ± 1.31 | − 0.19 ± 1.13 | 0.716 |
eGFR | − 17.27 ± 24.87 | 2.84 (− 7.1–22.08) | 0.052 |
Hypercholesterolemia | 1 (3.70%) | 2 (7.14%) | 1 |
Hypertriglyceridemia | 3 (11.11%) | 5 (17.86%) | 0.744 |
Elevated LDL | 1 (3.70%) | 0 (0%) | 0.49 |
Elevated HDL | 2 (7.41%) | 8 (28.57%) | 0.092 |
Elevated creatinine | 3 (11.11%) | 1 (3.57%) | 0.577 |